| ¿µ¹® | development | ÇÑ±Û | ¹ß´Þ, ¹ß»ý, ¹ßÀ° |
|---|---|---|---|
| ¼³¸í | 1. ¹ß´Þ. ½É½ÅÀÇ ÇüÅÂ¿Í Àç´ÉÀÇ »ó½ÂÀûÀÎ º¯È°úÁ¤. ¼ºÀå°ú ¸Å¿ì À¯»çÇÑ °³³äÀ¸·Î, ¶§·Î´Â °°Àº ¶æÀ¸·Î ¾²ÀÌ´Â °æ¿ìµµ ÀÖ´Ù. ±×·¯³ª ¼ºÀåÀº °³Ã¼ÀÇ ¹ßÀ°¿¡ µû¸£´Â º¯È, Áï °è¿ÀûÀ¸·Î ¾çÀûÀÎ Áõ°¡·Î¼ ±â¼úÇÏ´Â °æ¿ì¿¡ ¸¹ÀÌ ¾²À̰í, ¹ß´ÞÀº ÀÌ¿Í °°Àº º¯È¸¦ ¾çÀûÀÎ ¸é»Ó¸¸ ¾Æ´Ï¶ó, ±¸Á¶³ª Àç´ÉÀÌ ºÐÈ-º¹ÀâÈ-Á¤¹ÐÈ-À¯´ÉÈ-ÅëÇÕÈµÇ¾î °¡´Â °ÍÀ¸·Î¼ ±â¼úÇÏ´Â °æ¿ì¿¡ ´õ¿í ¸¹ÀÌ ¾²ÀÌ´Â °æÇâÀÌ ÀÖ´Ù. ±×¸®°í ¹ß´ÞÀ̶ó°í ÇÏ´Â °³³äÀº, À¯±âüÀÇ ¹ßÀ°¿¡ ´ëÇØ¼¸¸ ¾²ÀÌ´Â °ÍÀÌ ¾Æ´Ï¶ó, ¹«»ý¹°À̳ª ¹°¸®Àû-ÈÇÐÀû Çö»ó¿¡ ´ëÇØ¼µµ ¶Ç´Â »çȸÀû-¹®ÈÀû Çö»ó¿¡ ´ëÇØ¼µµ ½Ã°£Àû º¯È¹ßÀüÀ» ¼ö¹ÝÇÏ´Â °æ¿ì¿¡ Àû¿ëµÇ´Â °³³äÀÌ´Ù. 2. ¹ßÀ°. ¹ßÀ°°úÁ¤¿¡´Â ´ÙÀ½°ú °°Àº ÀϹÝÀûÀÎ ¿øÄ¢À» º¸ÀδÙ. ¨ç ¹ßÀ°Àº Áú¼Á¤¿¬ÇÏ°Ô ÀÏÁ¤ÇÑ ¼ø¼¸¦ °®´Â´Ù. ¨è ¹ßÀ°Àº ¿¬¼ÓÀûÀ̳ª ÀÏÁ¤ÇÑ ¼Óµµ·Î ÁøÇàÇÏ´Â °ÍÀº ¾Æ´Ï´Ù. ¨é ¹ßÀ°¿¡´Â ¹ßÀ°»ó Áß¿äÇÑ °¨¼ö±â¿Í ÀÓ°è±â°¡ ÀÖ´Ù. |
||
| ¿µ¹® | VDRL(venereal disease research laboratory) | ÇÑ±Û | ¼ºº´ ¿¬±¸½ÇÇè½Ç |
|---|---|---|---|
| ¼³¸í | ¸Åµ¶±ÕÀÇ reagin¿¡ ´ëÇÑ Ç×ü. ¸Åµ¶ÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ¸ç ¸Åµ¶ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ ¿©ºÎ¿Í Ä¡·áÈ¿°ú ÆÇÁ¤¿¡µµ »ç¿ëµÈ´Ù. ¸Åµ¶¿Ü¿¡µµ Àü½Å¼ºÈ«¹Ý¼º³¶Ã¢, ·ù¸¶Æ¼½º°üÀý¿° µî¿¡¼µµ ¾ç¼ºÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | Dilatation and Curettage(D & C) | ÇÑ±Û | Àڱñܾ¼ú, ÀڱøñÈ®Àå |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀ̶õ žư¡ ¼öÅÂµÇ¾î¼ ºÐ¸¸Àü±îÁö ¹ßÀ°ÇÏ°í ¼ºÀåÇÏ´Â °ø°£ÀÌ´Ù. Àڱüӿ¡ º´º¯ÀÌ ÀÖ¾î ÀÓ½ÅÀÌ °è¼ÓµÉ ¼ö ¾ø°Å³ª ¾Æ´Ï¸é ´Ù¸¥ ÀÌÀ¯·Î ÀӽŵǾî Àִ žƸ¦ Á¦°ÅÇϰíÀÚ ÇÒ °æ¿ì¿¡ »ç¿ëµÇ´Â ¹æ¹ýÀÌ´Ù. ¿©±â¼ ±Ü¾î³»±â À§ÇÏ¿©´Â ¿ì¼± ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ÀڱøñÀ» È®Àå½ÃÄÑ¾ß ÇÑ´Ù. ¿©±â¿¡´Â ±Þ¼ÓÈ÷ È®ÀåÀ» ½ÃµµÇÏ´Â ¹ý°ú ¼¼È÷ È®ÀåÀ» ½ÃµµÇÏ´Â 2°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀڱøñÀ» ±Þ¼ÓÈ÷ È®ÀåÇÒ ¶§´Â Çì°¡¸£ ¸ñ°üÈ®Àå±â(Hegar's dilatator)¸¦ »ç¿ëÇÑ´Ù. À̰ÍÀº ÀÛÀº ±Ý¼Ó¸·´ë·Î ÀÛÀº Å©±âºÎÅÍ Å« Å©±â±îÁö ´Ù¾çÇÑ Å©±â°¡ ÀÖ¾î¼ ¿ì¼± ÀÛÀº ¸·´ë·Î ½ÃÀÛÇÏ¿© Á¡Á¡ Å« Å©±âÀÇ ¸·´ë¸¦ Àڱøñ¿¡ ³Ö¾î¼ ÀڱøñÀ» È®Àå½ÃŲ´Ù. ¼¼È÷ È®Àå½Ãų ¶§´Â Laminaria tent¸¦ ¸ñ°ü¿¡ »ðÀÔÇÏ´Â ¹æ¹ýÀ» »ç¿ëÇÑ´Ù. Laminaria tent¶õ ÇØÃÊ·Î ¸¸µç ÀÛÀº ¸·´ë·Î ¼öºÐÀ» Èí¼öÇϸé Á¡Á¡ ´Ã¾î³ª´Â ¼ºÁúÀÌ ÀÖ´Ù. À̰ÍÀ» ÀÚ±ÃÀÇ ¸ñ¿¡ ³ÖÀ¸¸é À̰ÍÀÌ ¼öºÐÀ» Èí¼öÇÏ¿© ´Ã¾î³ª¹Ç·Î õõÈ÷ ÀÚ±ÃÀÇ ¸ñÀÌ ´Ã¾î³´Ù. ÀڱøñÀÌ ÃæºÐÈ÷ ´Ã¾î³ª¸é ±× ¼ÓÀ¸·Î ³¡ÀÌ ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ ³Ö¾î¼ ÀڱüÓÀÇ º´º¯À̳ª ÀÓ½ÅµÈ Å¾Ƹ¦ ±Ü¾î³»´Âµ¥ ¿©±â¿¡ »ç¿ëµÇ´Â ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ Å¥·¿À̶ó°í ÇÑ´Ù. Ãʱâ ÀÓ½ÅÁßÀý Áï À¯»ê°ú °°Àº ÀӽŰú °ü·ÃµÈ °æ¿ì»Ó¸¸ ¾Æ´Ï¶ó, ºñÀӽŠÀÚ±ÃÀÇ Àڱ󻸷Á¶Á÷ÀÇ Ã¤Ãë ¹× Á¦°Å¸¦ À§Çؼµµ ÇàÇØÁö´Â ¼ö±âÀÌ´Ù. ÀÌ´Â ¿øÄ¢ÀûÀ¸·Î ¸¶ÃëÇÏ¿¡ ½Ç½ÃµÇ´Â °ÍÀ¸·Î Àڱøñ°üÀ» È®ÀåÇÏ°í ±â±¸·Î Àڱà ³»¿ë¹°À» Á¦°ÅÇϰí Å¥·¿À¸·Î Àڱ󻺮À» ±ú²ýÀÌ ÇÑ´Ù. ÀÚ±Ãõ°øÀ̳ª ÀڱøñÀÇ ÆÄ¿ µîÀÇ À§ÇèÀÌ µû¸£¸ç, ¼ö¼úÈÄ °¨¿° ¶Ç´Â ÃâÇ÷ µî¿¡ ´ëÇÑ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù. |
||
| ¿µ¹® | antihypertensive drug | ÇÑ±Û | °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦ |
|---|---|---|---|
| ¼³¸í | °íÇ÷¾ÐÀÇ Ä¡·á¿¡ »ç¿ëÇÏ¸ç ³ôÀº Ç÷¾ÐÀ» ³·Ãß´Â ¾à¹°À» ¸»ÇÑ´Ù. °íÇ÷¾Ð¾à¿¡´Â Ç÷°üÆòȰ±Ù¿¡ Á÷Á¢ ÀÛ¿ëÇÏ¿© À̿ϽÃŰ´Â Ç÷°üÈ®ÀåÁ¦(È÷µå¶ó¶óÁø), ±³°¨½Å°æÀÇ È°µ¿À» ¾îµð¼±°¡ Â÷´ÜÇÏ´Â ¾à¹°(·¹¼¼¸£ÇÉ, ¸ÞÆ¿µµÆÄ, ÇÁ·ÎÇÁ¶ó³ë·Ñ), ÀÌ´¢Á¦(ÇÁ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)ÀÌ »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | antimalarial drug | ÇÑ±Û | ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦ |
|---|---|---|---|
| ¼³¸í | ¸»¶ó¸®¾Æ Ä¡·á¿¡ ¾²´Â ¾à. Ű´Ï³×, Ŭ·Î·ÎÄý, ÇÁ¸®¸¶Äý µûÀ§°¡ ÀÖ´Ù. ¸»¶ó¸®¾Æ ¿øÃæÀÇ ¹ßÀ°Áֱ⿡ ´ëÀÀÇØ¼ ¾à¹°ÀÌ ÀÖÀ¸³ª ´ëºÎºÐÀº º´¿ë¿ä¹ý¿¡ µû¶ó¼ ¸»¶ó¸®¾Æ Ä¡·á¸¦ ÇÑ´Ù. ¸ð±â¿¡ ÀÇÇÑ Æ÷ÀÚü°¨¿°¿¡ ´ëÇÑ Çׯ÷ÀÚü ¾àÀº µ¶¼º µîÀÇ ¹®Á¦°¡ ÀÖ¾î¼ ¾ÆÁ÷ ¾ø´Ù. ÀûÇ÷±¸³»¿¡¼ÀÇ È¯»óü, ¹ø½Äü¿¡¸¸ ÀÛ¿ëÇÏ´Â °Í(Ç×¹ø½Äü ¾àÀº Ŭ·Î·ÎÄý, ÇǸ®¸ÞŸ¹Î, Ŭ·Î·Î±¸¾Æ³ªÀ̵å, Ű´Ï³×)Àº ÀûÇ÷±¸ ¿ÜÀÇ ¹ßÀ°Àº ¾ïÁ¦ÇÏÁö ¾ÊÀ¸¹Ç·Î °¨¿°À» ¿ÏÀüÈ÷ ÀúÁöµÇÁö ¾Ê´Â´Ù. ÀûÇ÷±¸³»¿ÜÀÇ ¿øÃæ¿¡ ÀÛ¿ëÇØ ¿ÏÀüÈ÷ °¨¿°À» ¾ïÁ¦ÇÏ´Â °Í(ÆÄ¸¶Å², ÆæÅ¸Å², ÇÁ¸®¸¶Å²), Ç÷ÁßÀÇ »ý½Äü¸¦ Á×ÀÌ´Â °Í(´ëºÎºÐÀÇ Ç׸»¶ó¸®¾ÆÁ¦)Àº ¸ð±â¿¡ ÀÇÇÑ Å¸ÀÎÀ¸·ÎÀÇ Àü¿°¿øÀº ²÷±â´Âµ¥ ȯÀÚÀÚ½ÅÀÇ Áõ»óÀº º¯ÈÇÏÁö ¾Ê´Â´Ù. |
||
| CR | calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio... |
|---|---|
| JOC | Journal of Oncologic Clinical(?) |
| DA | dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis... |
| CS | calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ... |
| CHARGE | coloboma, heart disease, atresia choanae, retarded growth and retarded development and/or CNS anomal... |
| R&D | Research and Development |
|---|---|
| CDER | Center for Drug Evaluation and Research |
| JAMA | Journal of the American Medical Association |
| NEJM | New England Journal of Medicine |
| CPCRA | Community Programs for Clinical Research in AIDS |
| journal article | The predominant publication type for articles and other items indexed for nlm databases. (12 Dec 1998) |
|---|---|
| clinical nursing research | Research carried out by nurses in the clinical setting and designed to provide information that will help improve patient care. Other professional staff may also participate in the research. (12 Dec 1998) |
| clinical research trials | Evaluating the safety and effectiveness of medications or medical devices by monitoring their effects on large groups of people. Clinical medical trials sponsored by the U. S. Government are listed on a web site of the National Institutes of Health (NIH). The NIH Clinical Centre intends to make details of current clinical research studies for various diseases available over the Internet to increase opportunities for patients and physicians to participate in clinical investigations. (12 Dec 1998) |
| drug development pathway | The various procedures and studies that must be undertaken to satisfy Food and Drug Administration requirements for drug approval and marketing. (14 Nov 1997) |
| united states agency for health care policy and research | An agency of the public health service established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery.." it supersedes the national centre for health services research. (12 Dec 1998) |
| growth and embryonic development | Developmental processes from cell division to embryogenesis to postnatal growth and maturity. (12 Dec 1998) |
| state health planning and development agencies | Agencies established under pl93-641 to coordinate, conduct, and implement state health planning activities. Two primary responsibilities are the preparation of an annual state health plan and giving assistance to the statewide health coordinating council. (12 Dec 1998) |
| land conservation and development commission | (LCDC) A commission appointed to determine land use policy in Oregon. (05 Dec 1998) |
| drug-drug interaction | The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity. (09 Oct 1997) |
| drug and narcotic control | Control of drug and narcotic use by international agreement, or by institutional systems for handling prescribed drugs. This includes regulations concerned with the manufacturing, dispensing, approval (drug approval), and marketing of drugs. (12 Dec 1998) |
| united states food and drug administration | An agency of the public health service concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc. (12 Dec 1998) |
| food and drug administration | The U.S. Agency responsible for regulation of biotechnology foodproducts. The major laws under which the agency has regulatory powersinclude the Food, Drug, and Cosmetic act, and the Public Health Service Act. (09 Oct 1997) |
| Venereal Disease Research Laboratory | <microbiology> A blood test used to diagnose syphilis. Read as nonreactive or negative if you do not have syphilis. The Venereal Disease Research Laboratory can also be positive is cases of leprosy, malaria, mononucleosis, lupus, hepatitis A and pregnancy. Positive Venereal Disease Research Laboratory tests are usually followed up by a more specific test (FTA antibodies). (12 Jan 1998) |
| Medical Research Council | <organisation> A UK Government funded body to promote the balanced development of medical and related biological research in the United Kingdom. It organises national clinical trials for the assessment of new treatment protocols for leukaemia and some of the related diseases. (05 Jan 1998) |
| research | Careful, a diligent search, a close searching, studious inquiry or examination. (18 Nov 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|